Patents by Inventor Mildred Acevedo-Duncan
Mildred Acevedo-Duncan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11446264Abstract: Provided is a method of inhibiting protein kinase C zeta/protein kinase M zeta, including contacting a sample containing an isoform of protein kinase C zeta with a compound of formula: referred to as 1-naphthol-3,6,8-trisulphonic acid, or a pharmaceutically acceptable salt thereof. In some embodiments, contacting the sample with the compound does not inhibit protein kinase C iota/lambda. In a specific example, the sample includes neural tissue, the isoform of protein kinase C zeta is protein kinase M zeta, and inhibiting includes reducing kinase activity and further includes diminishing long-term potentiation. In some embodiment, the method includes inhibiting glucose transport. Also provided is a method of affecting memory, including administering the compounds to a mammalian organism.Type: GrantFiled: October 15, 2018Date of Patent: September 20, 2022Assignees: THE RESEARCH FOUNDATION FOR THE STATE UNIVERISTY OF NEW YORK, UNIVERSITY OF SOUTH FLORIDAInventors: Todd Sacktor, Mildred Acevedo-Duncan
-
Publication number: 20220241226Abstract: The subject invention pertains to methods of treating colorectal cancer by administering an atypical PKC inhibitor. The inhibitors of aPKC useful in the methods of the instant invention include ACPD, ICA-1, DNDA and ?-Stat. Also provided are methods of measuring the susceptibility of colon cancer cells of a subject to inhibitors of aPKCs.Type: ApplicationFiled: April 22, 2022Publication date: August 4, 2022Inventors: Mildred ACEVEDO-DUNCAN, Anisul ISLAM, David A. OSTROV
-
Patent number: 11337944Abstract: The subject invention pertains to methods of treating colorectal cancer by administering an atypical PKC inhibitor. The inhibitors of aPKC useful in the methods of the instant invention include ACPD, ICA-1, DNDA and ?-Stat. Also provided are methods of measuring the susceptibility of colon cancer cells of a subject to inhibitors of aPKCs.Type: GrantFiled: July 6, 2017Date of Patent: May 24, 2022Assignees: UNIVERSITY OF SOUTH FLORIDA, UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.Inventors: Mildred Acevedo-Duncan, Anisul Islam, David A. Ostrov
-
Publication number: 20200261384Abstract: Provided is a method of inhibiting protein kinase C zeta/protein kinase M zeta, including contacting a sample containing an isoform of protein kinase C zeta with a compound of formula: referred to as 1-naphthol-3,6,8-trisulphonic acid, or a pharmaceutically acceptable salt thereof. In some embodiments, contacting the sample with the compound does not inhibit protein kinase C iota/lambda. In a specific example, the sample includes neural tissue, the isoform of protein kinase C zeta is protein kinase M zeta, and inhibiting includes reducing kinase activity and further includes diminishing long-term potentiation. In some embodiment, the method includes inhibiting glucose transport. Also provided is a method of affecting memory, including administering the compounds to a mammalian organism.Type: ApplicationFiled: October 15, 2018Publication date: August 20, 2020Applicant: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORKInventors: Todd SACKTOR, Mildred ACEVEDO-DUNCAN
-
Publication number: 20200078323Abstract: A method of inhibiting the growth or proliferation of ovarian cancer cells is provided. The method comprises contacting the ovarian cancer cells with an effective amount of 8-hydroxynaphthalene-1,3,6-trisulfonic acid (?-Stat), a salt of ?-Stat, a derivative of ?-Stat, or a salt of a derivative of ?-Stat. Also provided is a method of treating an ovarian cancer or inhibiting ovarian cancer cell growth or proliferation in a subject by administering to the subject a therapeutically effective amount of ?-Stat, a salt of ?-Stat, a derivative of ?-Stat, or a salt of a derivative of ?-Stat.Type: ApplicationFiled: September 12, 2019Publication date: March 12, 2020Applicant: University of South FloridaInventors: Mildred ACEVEDO-DUNCAN, Tracess SMALLEY, Rekha PATEL
-
Publication number: 20180008564Abstract: The subject invention pertains to methods of treating colorectal cancer by administering an atypical PKC inhibitor. The inhibitors of aPKC useful in the methods of the instant invention include ACPD, ICA-1, DNDA and ?-Stat. Also provided are methods of measuring the susceptibility of colon cancer cells of a subject to inhibitors of aPKCs.Type: ApplicationFiled: July 6, 2017Publication date: January 11, 2018Applicant: University of South FloridaInventor: Mildred Acevedo-Duncan
-
Publication number: 20170304223Abstract: The invention relates to compositions comprising a PKC inhibitor and their use in a method of treating or preventing the development of prostate cancer.Type: ApplicationFiled: April 24, 2017Publication date: October 26, 2017Inventors: Mildred Acevedo-Duncan, Andre Apostolatos
-
Patent number: 8603758Abstract: A method of detecting prostate tumorigenesis in a subject, the method including the steps of (a) obtaining a sample from the prostate of the human subject, (b) detecting quantitatively or semi-quantitatively in the sample a level of expression for PKC-? and (c) comparing the expression level in (b) to a level of expression in a normal control, wherein overexpression of PKC-?, with respect to the control, indicates the presence of prostate cancer in the subject. The present invention is based upon the discovery that PKC-? levels are elevated during prostate tumorigenesis. Furthermore, the proliferation rate of the tumor correlates with the level of PKC-?. The invention also provides methods of treating prostate cancer by administering to the subject a compound that inhibits the expression of PKC-?. The compound can be a small interfering RNA (siRNA) molecule.Type: GrantFiled: June 25, 2012Date of Patent: December 10, 2013Assignees: University of South Florida, The United States of America as represented by the Department of Veterans AffairsInventors: Mildred Acevedo-Duncan, Hla Y. Win, Raoul Salup
-
Patent number: 8461192Abstract: PKCiota inhibitor 1H-imidazole-4-carboxamide, 5-amino-1-[2,3-dihydroxy-4-[(phosphonooxy)methyl]cyclopentyl]-,[1R-(1?,2?,3?,4?)], (ICA-1), targets a unique sequence (amino acid residues 469-475) in the catalytic domain of PKCiota and inhibits PKCiota activity. The data shows suprising and unexpected ability of ICA-1 to selectively inhibit the proliferation of cells that overexpress PKCiota.Type: GrantFiled: September 15, 2008Date of Patent: June 11, 2013Assignees: The University of South Florida, The United States of America Department of Veterans Affairs, The University of Florida Research Foundation, Inc.Inventors: Mildred Acevedo-Duncan, Shraddha R. Desai, Hla Yee Win, David A. Ostrov, Prajit P. Pillai, Diondra D. Hill
-
Publication number: 20120294932Abstract: A method of detecting prostate tumorigenesis in a subject, the method including the steps of (a) obtaining a sample from the prostate of the human subject, (b) detecting quantitatively or semi-quantitatively in the sample a level of expression for PKC-? and (c) comparing the expression level in (b) to a level of expression in a normal control, wherein overexpression of PKC-?, with respect to the control, indicates the presence of prostate cancer in the subject. The present invention is based upon the discovery that PKC-? levels are elevated during prostate tumorigenesis. Furthermore, the proliferation rate of the tumor correlates with the level of PKC-?. The invention also provides methods of treating prostate cancer by administering to the subject a compound that inhibits the expression of PKC-?. The compound can be a small interfering RNA (siRNA) molecule.Type: ApplicationFiled: June 25, 2012Publication date: November 22, 2012Applicant: University of South FloridaInventors: Mildred Acevedo-Duncan, Hla Y. Win, Raoul Salup
-
Publication number: 20120171219Abstract: The present invention provides use of protein kinase C-zeta (PKC-?) as a diagnostic biomarker for breast cancer tumorigenesis. Also provided are uses of PKC-zeta inhibitors for inhibiting breast cancer tumorigenesis and for treatment of breast cancer.Type: ApplicationFiled: December 1, 2011Publication date: July 5, 2012Applicants: United States Department of Veterans Affairs, University of South FloridaInventors: Mildred Acevedo-Duncan, Diondra D. Hill
-
Publication number: 20090181077Abstract: A method of detecting brain tumorigenesis in a subject, the method including the steps of (a) obtaining a sample from the brain of the human subject, (b) detecting quantitatively or semi-quantitatively in the sample a level of expression for PKC-iota and (c) comparing the expression level in (b) to a level of expression in a normal control, wherein overexpression of PKC-iota, with respect to the control, indicates the presence of a glioma or meningioma in the subject. The present invention is based upon the discovery that PKC-iota levels are elevated during brain tumorigenesis. Furthermore, the proliferation rate of the tumor correlates with the level of PKC-iota. The invention also provides methods of treating gliomas and meningiomas by administering to the subject a compound that inhibits the expression of PKC-iota. The compound can be a small interfering RNA (siRNA) molecule.Type: ApplicationFiled: December 19, 2008Publication date: July 16, 2009Applicants: UNITED STATES DEPARTMENT OF VETERANS AFFAIRS, UNIVERSITY OF SOUTH FLORIDAInventors: Mildred Acevedo-Duncan, Rekha Patel
-
Publication number: 20090130195Abstract: A method of detecting prostate tumorigenesis in a subject, the method including the steps of (a) obtaining a sample from the prostate of the human subject, (b) detecting quantitatively or semi-quantitatively in the sample a level of expression for PKC-? and (c) comparing the expression level in (b) to a level of expression in a normal control, wherein overexpression of PKC-?, with respect to the control, indicates the presence of prostate cancer in the subject. The present invention is based upon the discovery that PKC-? levels are elevated during prostate tumorigenesis. Furthermore, the proliferation rate of the tumor correlates with the level of PKC-?. The invention also provides methods of treating prostate cancer by administering to the subject a compound that inhibits the expression of PKC-?. The compound can be a small interfering RNA (siRNA) molecule.Type: ApplicationFiled: October 17, 2008Publication date: May 21, 2009Inventors: Mildred Acevedo-Duncan, Hla Y. Win, Raoul Salup
-
Publication number: 20090075932Abstract: PKCiota inhibitor 1H-imidazole-4-carboxamide, 5-amino-1-[2,3-dihydroxy-4-[(phosphonooxy)methyl]cyclopentyl]-,[1R-(1?,2?,3?,4?)], (ICA-1), targets a unique sequence (amino acid residues 469-475) in the catalytic domain of PKCiota and inhibits PKCiota activity. The data shows suprising and unexpected ability of ICA-1 to selectively inhibit the proliferation of cells that overexpress PKCiota.Type: ApplicationFiled: September 15, 2008Publication date: March 19, 2009Applicants: UNIVERSITY OF SOUTH FLORIDA, UNITED STATES DEPARTMENT OF VETERANS AFFAIRS, UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.Inventors: Mildred Acevedo-Duncan, Shraddha R. Desai, Hla Yee Win, David A. Ostrov, Prajit P. Pillai, Diondra D. Hill
-
Patent number: 7482131Abstract: A method of detecting brain tumorigenesis in a subject, the method including the steps of (a) obtaining a sample from the brain of the human subject, (b) detecting quantitatively or semi-quantitatively in the sample a level of expression for PKC-iota and (c) comparing the expression level in (b) to a level of expression in a normal control, wherein overexpression of PKC-iota, with respect to the control, indicates the presence of a glioma or meningioma in the subject. The present invention is based upon the discovery that PKC-iota levels are elevated during brain tumorigenesis. Furthermore, the proliferation rate of the tumor correlates with the level of PKC-iota. The invention also provides methods of treating gliomas and meningiomas by administering to the subject a compound that inhibits the expression of PKC-iota. The compound can be a small interfering RNA (siRNA) molecule.Type: GrantFiled: November 15, 2006Date of Patent: January 27, 2009Assignees: United States Department of Veterans Affairs, University of South FloridaInventors: Mildred Acevedo-Duncan, Rekha Patel
-
Publication number: 20070166733Abstract: A method of detecting brain tumorigenesis in a subject, the method including the steps of (a) obtaining a sample from the brain of the human subject, (b) detecting quantitatively or semi-quantitatively in the sample a level of expression for PKC-iota and (c) comparing the expression level in (b) to a level of expression in a normal control, wherein overexpression of PKC-iota, with respect to the control, indicates the presence of a glioma or meningioma in the subject. The present invention is based upon the discovery that PKC-iota levels are elevated during brain tumorigenesis. Furthermore, the proliferation rate of the tumor correlates with the level of PKC-iota. The invention also provides methods of treating gliomas and meningiomas by administering to the subject a compound that inhibits the expression of PKC-iota. The compound can be a small interfering RNA (siRNA) molecule.Type: ApplicationFiled: November 15, 2006Publication date: July 19, 2007Applicant: University of South FloridaInventors: Mildred Acevedo-Duncan, Rekha Patel